Market Overview
Global CHD Closure Devices market was valued at USD 252 million in 2024. The market is projected to grow from USD 269 million in 2025 to USD 392 million by 2031, exhibiting a CAGR of 6.7% during the forecast period.
CHD closure devices are specialized medical implants designed to seal congenital heart defects (CHDs) through minimally invasive procedures. These devices primarily include atrial septal defect (ASD) occluders, ventricular septal defect (VSD) occluders, and patent ductus arteriosus (PDA) occluders, which address different types of structural abnormalities in the heart's chambers and vessels.
USD 252 million in 2024
2032
USD 392 million by 2031,
CAGR of 6.7%
By Type
ASD Occluder Segment Dominates the Market Due to its High Prevalence in Congenital Heart Defect Cases
The market is segmented based on type into:
ASD Occluder
VSD Occluder
PDA Occluder
By Application
Hospitals Segment Leads Due to the Concentration of Advanced Interventional Cardiology Procedures
The market is segmented based on application into: Hospitals Clinics
Portable Neuromonitoring Device Market
Leading companies in the CHD Closure Devices market include Abbott, Boston Scientific, LifeTech, Lepu Medical, Occlutech, W. L. Gore & Associates, Starway, Coherex Medical, Cardia, and MicroPort. These players collectively hold a significant share of the global market, driven by their robust product portfolios and strategic expansions into high-growth regions.
Our Key Players
Abbott (U.S.)
Boston Scientific (U.S.)
LifeTech (China)
Lepu Medical (China)
Occlutech (Sweden)
W. L. Gore & Associates (U.S.)
https://www.24lifesciences.com/downloadsample/2784/chd-closure-devices-marketmarket
https://www.24lifesciences.com
